Yep, agree. This has tremendous potential. If I had to bet on a single ASX speccy to ten bag within 18 months, I'd choose NYR, based purely on cholesterol.
"A key advantage of the Phase I study is not only will it measure the safety and tolerability of Nyrada’s drug candidate, but it will also evaluate its efficacy"
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.005(2.27%) |
Mkt cap ! $47.45M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 22.5¢ | 22.5¢ | $12.02K | 53.43K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 201320 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 76295 | 2 |
View Market Depth
| Last trade - 10.58am 25/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |